Full Press Release Details
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft (PDX) models.
"This license marks a significant milestone in our capability to support biopharmaceutical partners in developing next-generation radiotherapeutics," stated Ronnie Morris, CEO of Champions Oncology. "By integrating this expertise with our well-characterized PDX platform, we are uniquely positioned to drive the advancement of radiopharmaceutical development with unparalleled translational precision."
This comprehensive program will support drug developers across a range of modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.
For partnership inquiries or to learn more, please contact us at https://www.championsoncology.com/contact-us .